Projected increase in amyotrophic lateral sclerosis from 2015 to 2040

Although amyotrophic lateral sclerosis (ALS) is relatively rare, the socioeconomic significance of the disease is extensive. It is therefore vital to project the epidemiologic trend of ALS. To date, there have been few published studies attempting to estimate the number and distribution of ALS cases in the upcoming years. Here we show that the number of ALS cases across the globe will increase from 222,801 in 2015 to 376,674 in 2040, representing an increase of 69%. This increase is predominantly due to ageing of the population, particularly among developing nations. This projection is likely an underestimate due to improving healthcare and economic conditions. The results should be used to inform healthcare policy to more efficiently allocate healthcare resources.

[1]  S Quick,et al.  International data base. , 1984, POPIN bulletin.

[2]  K. Radhakrishnan,et al.  Descriptive epidemiology of motor neuron disease in Benghazi, Libya. , 1986, Neuroepidemiology.

[3]  Evon M. O. Abu-Taieh,et al.  Comparative study , 2003, BMJ : British Medical Journal.

[4]  B. Brooks,et al.  El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.

[5]  [Clinical aspects of amyotrophic lateral sclerosis]. , 1996, Wiener medizinische Wochenschrift.

[6]  T. Koepsell,et al.  Incidence of amyotrophic lateral sclerosis in three counties in western Washington state , 1996, Neurology.

[7]  T. Pekmezović,et al.  Epidemiological and clinical characteristics of ALS in Belgrade, Yugoslavia , 1996, Acta neurologica Scandinavica.

[8]  J P Wenzlick,et al.  Two steps forward, one step back. , 1997, InfoCare : information strategies for healthcare networks.

[9]  J. Barendregt,et al.  Global burden of disease , 1997, The Lancet.

[10]  R. Bonita,et al.  Global health status: two steps forward, one step back , 2000, The Lancet.

[11]  T D Koepsell,et al.  Prognosis in amyotrophic lateral sclerosis , 2003, Neurology.

[12]  H. Okumura.  Epidemiological and clinical patterns of western pacific amyotrophic lateral sclerosis (ALS) in Guam and sporadic ALS in Rochester, Minnesota, U.S.A. and Hokkaido, Japan: a comparative study. , 2003, [Hokkaido igaku zasshi] The Hokkaido journal of medical science.

[13]  Epidemiological and clinical patterns of Western Pacific amyotrophic lateral sclerosis (ALS) and sporadic ALS surveyed in Rochester, Minnesota, U.S.A. and Hokkaido, Japan : A comparative study , 2003 .

[14]  Adriano Chiò,et al.  Acute migraine treatment with droperidol , 2003, Neurology.

[15]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[16]  C. Bain,et al.  Essential Epidemiology: An Introduction for Students and Health Professionals , 2005 .

[17]  S. Ho,et al.  An epidemiological study of motor neuron disease in Hong Kong , 2005, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[18]  J. Avery.  Critical review. , 2006, The Journal of the Arkansas Medical Society.

[19]  F. Dominici,et al.  Reproducible epidemiologic research. , 2006, American journal of epidemiology.

[20]  C. Tanner,et al.  Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 , 2007, Neurology.

[21]  S. Cronin,et al.  Ethnic variation in the incidence of ALS , 2007, Neurology.

[22]  E. Beghi,et al.  Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[23]  M. Druet‐Cabanac,et al.  Incidence and Prevalence of Amyotrophic Lateral Sclerosis in Uruguay: A Population-Based Study , 2008, Neuroepidemiology.

[24]  P. Parkin,et al.  Increasing incidence of ALS in Canterbury, New Zealand , 2008, Neurology.

[25]  H. Tseng,et al.  Epidemiology and Medical Expenses of Motor Neuron Diseases in Taiwan , 2008, Neuroepidemiology.

[26]  E. Beghi,et al.  Incidence of amyotrophic lateral sclerosis in Europe , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[27]  鮫島 浩,et al.  Population-based study からみた神経予後不良因子の検討 , 2009 .

[28]  L. Perestelo-Pérez,et al.  Social economic costs and health-related quality of life in patients with amyotrophic lateral sclerosis in Spain , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[29]  E. Beghi,et al.  Prognostic factors in ALS: A critical review , 2009, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[30]  M. Hernán,et al.  Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population‐based study , 2009, European journal of neurology.

[31]  W. Oertel,et al.  Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy , 2009, Journal of Neurology.

[32]  M. Etemadifar,et al.  Epidemiology of amyotrophic lateral sclerosis in Isfahan, Iran , 2010, European journal of neurology.

[33]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[34]  L. Thuler,et al.  Clinical aspects of amyotrophic lateral sclerosis in Rio de Janeiro/Brazil , 2012, Journal of the Neurological Sciences.

[35]  A. Chiò,et al.  Global Epidemiology of Amyotrophic Lateral Sclerosis: A Systematic Review of the Published Literature , 2013, Neuroepidemiology.

[36]  J. Weuve,et al.  Alzheimer disease in the United States (2010–2050) estimated using the 2010 census , 2013, Neurology.

[37]  Ben Goldacre,et al.  Survival Analysis of Irish Amyotrophic Lateral Sclerosis Patients Diagnosed from 1995–2010 , 2013, PloS one.

[38]  N. Grassly,et al.  United Nations Department of Economic and Social Affairs/population Division , 2022 .

[39]  F. Collins,et al.  NIH plans to enhance reproducibility , 2014 .

[40]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[41]  Yuriko 由利子 Doi 土井,et al.  Prevalence and Incidence of Amyotrophic Lateral Sclerosis in Japan , 2014, Journal of epidemiology.

[42]  F. Collins,et al.  Policy: NIH plans to enhance reproducibility , 2014, Nature.

[43]  Marie-Claude Babron,et al.  Clinical and demographic factors and outcome of amyotrophic lateral sclerosis in relation to population ancestral origin , 2016, European Journal of Epidemiology.

[44]  S. Hollinghurst,et al.  Systematic review of the published literature , 2015 .

[45]  L. Zinman,et al.  The economic impact of amyotrophic lateral sclerosis: a systematic review , 2015, Expert review of pharmacoeconomics & outcomes research.